Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

When Columbus resident Jennifer Roberts’ family gets together for the holidays, they typically play a few games of bingo for ...

Jay and Pamela both have Osteogenesis Imperfecta Type 3, a condition that causes fragile bones. Both get around in motorized ...

Jay and Pamela take on their health struggles while also gearing up for their wedding in new docuseries "Jay and Pamela," ...

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

A new TLC reality series, Jay & Pamela, is just around the corner—and its stars are an engaged couple born with the same ...

Charlotte Proud, a Sunderland University apprentice born with Osteogenesis Imperfecta (Brittle Bone Disease), is determined ...

TLC seems particularly busy lately, announcing some new shows that take the channel in familiar directions and at least one ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...